Search results for " type 2"

showing 10 items of 761 documents

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide.

2020

Obesity has reached epidemic proportions in the United States and in much of the westernized world, contributing to considerable morbidity. Several of these obesity-related morbidities are associated with greater risk for death with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 penetrates human cells through direct binding with angiotensin-converting enzyme 2 receptors on the cell surface. Angiotensin-converting enzyme 2 expression in adipose tissue is higher than that in lung tissue, which means that adipose tissue may be vulnerable to COVID-19 infection. Obese patients also have worse outcomes with COVID-19 infection, including respiratory failure, n…

BMI body mass indexmedicine.medical_treatmentAdipose tissue030204 cardiovascular system & hematologyCHD coronary heart diseaseHF heart failureUS United States0302 clinical medicineRAAS renin-angiotensin-aldosterone systemPandemicMedicine030212 general & internal medicineCDC Centers for Disease Control and PreventionCOVID-19 coronavirus disease 2019TNF tumor necrosis factorHFpEF HF with preserved ejection fractionCV cardiovascularGeneral MedicinePrognosisICU intensive care unitPA physical activityMetS metabolic syndromePAH pulmonary arterial hypertensionCoronavirus Infectionsmedicine.medical_specialtyAF atrial fibrillationACE angiotensin-converting enzymePneumonia ViralCVD cardiovascular diseaseSARS-CoV-2 severe acute respiratory syndrome coronavirus 2ArticleSeverity03 medical and health sciencesBetacoronavirusInternal medicineIPF idiopathic pulmonary fibrosisHumansObesityMortalityHTN hypertension or hypertensivePandemicsMechanical ventilationAng II angiotensin IIbusiness.industrySARS-CoV-2CKD chronic kidney diseaseCOVID-19T2DM type 2 diabetes mellitusmedicine.diseaseAngiotensin IIObesityIL interleukinPneumoniaRespiratory failureMetabolic syndromebusinessSNS sympathetic nervousMayo Clinic proceedings
researchProduct

Analysis of the Impact of Disease Acceptance, Demographic, and Clinical Variables on Adherence to Treatment Recommendations in Elderly Type 2 Diabete…

2021

This project aimed to analyze the impact of disease acceptance and selected demographic and clinical factors on the adherence to treatment recommendations in elderly type 2 diabetes mellitus patients. The observational study was performed using standardized research questionnaires: the Acceptance of Illness Scale (AIS), the Self-Care of Diabetes Inventory (SCODI), and the Adherence in Chronic Diseases Scale (ACDS). Two hundred patients with T2DM were studied (age M = 70.21 years, SD = 6.63 years). The median degree of disease acceptance was 29 (min–max = 8–40) and the median level of adherence was 24 (min–max = 13–28). Disease acceptance was a significant (p = 0.002) independent predictor o…

Biopsychosocial modelmedicine.medical_specialtytype 2 diabetes mellitusHealth Toxicology and MutagenesisPsychological interventionDiseasecomplianceArticleMedication AdherenceSurveys and QuestionnairesDiabetes mellitusInternal medicineHumansMedicineadherenceDemographyGlycemicbusiness.industryPublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseSelf CareagedDiabetes Mellitus Type 2PillMedicineObservational studybusinessInternational Journal of Environmental Research and Public Health
researchProduct

Epigenetic markers associated with metformin response and intolerance in drug-naïve patients with type 2 diabetes

2020

Metformin is the first-line pharmacotherapy for managing type 2 diabetes (T2D). However, many patients with T2D do not respond to or tolerate metformin well. Currently, there are no phenotypes that successfully predict glycemic response to, or tolerance of, metformin. We explored whether blood-based epigenetic markers could discriminate metformin response and tolerance by analyzing genome-wide DNA methylation in drug-naïve patients with T2D at the time of their diagnosis. DNA methylation of 11 and 4 sites differed between glycemic responders/nonresponders and metformin-tolerant/intolerant patients, respectively, in discovery and replication cohorts. Greater methylation at these sites associ…

Blood Glucose0301 basic medicineOncologymedicine.medical_specialtyendocrine system diseases030209 endocrinology & metabolismType 2 diabetesEpigenesis Genetic03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsEpigeneticsGlycemicbusiness.industrynutritional and metabolic diseasesGeneral MedicineOdds ratioDNA Methylationmedicine.diseaseMetformin3. Good healthMetforminDrug-naïve030104 developmental biologyDiabetes Mellitus Type 2Pharmaceutical PreparationsDNA methylationbusinessmedicine.drugScience Translational Medicine
researchProduct

Incretins, Pregnancy, and Gestational Diabetes

2015

The number of pregnant women affected by gestational diabetes mellitus (GDM) is increasing among Caucasians, and East Asians. GDM also increases the risk for later advent of type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease in both women and their offspring. The underlying mechanism of GDM is not fully elucidated. Incretins such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), have been suggested to have a role in maternal metabolism and weight as well as fetal growth. These hormones might be implicated in mechanisms that compensate for the increment in glycemia and insulin resistance seen during pregnancy, while other factors, such a…

Blood Glucose0301 basic medicineendocrine systemmedicine.medical_specialtyendocrine system diseasesOffspringPharmaceutical ScienceIncretinGastric Inhibitory PolypeptideType 2 diabetes030204 cardiovascular system & hematologyIncretins03 medical and health sciences0302 clinical medicineInsulin resistanceGlucagon-Like Peptide 1PregnancyRisk FactorsInternal medicineGlucose IntoleranceAnimalsHumansMedicineObesityPregnancybusiness.industrynutritional and metabolic diseasesType 2 Diabetes MellitusType 2 diabetesIncretinmedicine.diseaseObesityGestational diabetesDiabetes Gestational030104 developmental biologyEndocrinologyGestational diabeteDiabetes Mellitus Type 2FemaleInsulin Resistancebusinesshormones hormone substitutes and hormone antagonistsBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct

GLP 1 receptor agonists, glycemic variability, oxidative stress and acute coronary syndrome

2020

Abstract Glycemic variability (GV) has been recently described as an independent cardiovascular risk factor in patients with acute coronary syndrome (ACS). Also, new findings suggest that GV plays an important role in the development of complications related to impaired glucose metabolism and oxidative stress. On the other hand, although treatment for diabetes can reduce HbA1c in a similar extent their effectiveness over GV can be radically different. Patients in the acute setting of a coronary syndrome should be strictly monitorized to maintain glucose within recommended values; avoiding values lower than 90 mg/dL (5 mmol/L) and higher than 180 mg/dL (10 mmol/L). Also, evidence suggests th…

Blood Glucose0301 basic medicinemedicine.medical_specialtyAcute coronary syndromeCarbohydrate metabolismmedicine.disease_causeGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusHumansInsulinMedicineAcute Coronary SyndromeRisk factorGlucagon-like peptide 1 receptorGlycemicbusiness.industryGeneral Medicinemedicine.diseaseOxidative StressGlucose030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2business030217 neurology & neurosurgeryOxidative stressMaceMedical Hypotheses
researchProduct

GLP2: An underestimated signal for improving glycaemic control and insulin sensitivity

2016

Glucagon-like peptide 2 (GLP2) is a proglucagon-derived peptide produced by intestinal enteroendocrine L-cells and by a discrete population of neurons in the brainstem, which projects mainly to the hypothalamus. The main biological actions of GLP2 are related to the regulation of energy absorption and maintenance of mucosal morphology, function and integrity of the intestine; however, recent experimental data suggest that GLP2 exerts beneficial effects on glucose metabolism, especially in conditions related to increased uptake of energy, such as obesity, at least in the animal model. Indeed, mice lacking GLP2 receptor selectively in hypothalamic neurons that express proopiomelanocortin show…

Blood Glucose0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulation030209 endocrinology & metabolismEnteroendocrine cellType 2 diabetesBiologyCarbohydrate metabolismDiet High-FatModels BiologicalType 2 diabeteMice03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologyInternal medicineGlucagon-Like Peptide 2medicineAnimalsHomeostasisHumansGlucose homeostasisObesityeducationeducation.field_of_studyGLP2Insulin resistanceGlucagon-like peptide-2medicine.disease030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2GLP2; Insulin resistance; Obesity; Type 2 diabetes; Endocrinology; Endocrinology Diabetes and MetabolismHomeostasisSignal Transduction
researchProduct

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin

2016

Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear(1). Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome-wide association study (GWAS), consisting of 13,123 participants of different ancestries. The C allele of rs8192675 in the intron of SLC2A2, which encodes the facilitated glucose transporter GLUT2, was associated with a 0.17% (P = 6.6 x 10(-14)) greater metformin-induced reduction in hemoglobin A1c (HbA1c) in 10,577 participants of European ancestry. rs8192675 was the top cis expression quantitative trait locus (cis-eQTL) for SLC2A2 in 1,226 human liver samples, suggesting a key role …

Blood Glucose0301 basic medicinemedicine.medical_specialtyendocrine system diseasesGenome-wide association studyType 2 diabetesPolymorphism Single NucleotideWhite PeopleBody Mass Index03 medical and health sciencesQuantitative Trait HeritableInternal medicineDiabetes mellitusGeneticsmedicineHumansHypoglycemic AgentsAlleleGlycemicGlucose Transporter Type 2Glycated HemoglobinbiologyGlucose transporternutritional and metabolic diseasesmedicine.diseaseMetformin3. Good healthMetformin030104 developmental biologyEndocrinologyDiabetes Mellitus Type 2biology.proteinGLUT2Genome-Wide Association Studymedicine.drug
researchProduct

Exercise and Metformin Intervention Prevents Lipotoxicity-Induced Hepatocyte Apoptosis by Alleviating Oxidative and ER Stress and Activating the AMPK…

2022

Objective. Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) commonly coexist and act synergistically to drive adverse clinical outcomes. This study is aimed at investigating the effects of exercise intervention and oral hypoglycaemic drug of metformin (MET) alone or combined on hepatic lipid accumulation. To investigate if oxidative stress and endoplasmic reticulum stress (ERS) are involved in lipotoxicity-induced hepatocyte apoptosis in diabetic mice and whether exercise and/or MET alleviated oxidative stress or ERS-apoptosis by AMPK-Nrf2-HO-1 signaling pathway. Methods. Forty db/db mice with diabetes ( random   blood   glucose ≥ 250   mg / dL ) were randomly allocated i…

Blood GlucoseAgingArticle SubjectNF-E2-Related Factor 2metformiiniApoptosisAMP-Activated Protein KinasesBiochemistryAntioxidantsDiabetes Mellitus ExperimentalMiceohjelmoitunut solukuolemaSuperoxide Dismutase-1aineenvaihduntahäiriötAnimalsHypoglycemic AgentsHematoxylinoksidatiivinen stressibcl-2-Associated X ProteinCaspase 3Cell BiologyGeneral MedicineEndoplasmic Reticulum StressLipidsMetforminOxidative StressDiabetes Mellitus Type 2ei-alkoholiperäinen rasvamaksasairausHepatocyteslääkehoitoEosine Yellowish-(YS)koe-eläinmallitaikuistyypin diabetesSignal TransductionliikuntahoitoOxidative Medicine and Cellular Longevity
researchProduct

Frequent and severe hypoglycaemia detected with continuous glucose monitoring in older institutionalised patients with diabetes.

2021

AbstractBackgroundLittle is known about the prevalence of hypoglycaemia in older people with diabetes. However, the HbA1c goal is ≥8% for institutionalised patients with treatments that can cause hypoglycaemia.PurposeWe aimed to assess the prevalence of hypoglycaemia with continuous glucose monitoring and to evaluate the link with HbA1C in older institutionalised patients with diabetes taking potentially hypoglycaemia-inducing drugs.DesignProspective, multicentre study carried out in six geriatric care centres in the Côte d’Or region of France between January 2019 and July 2020.Settings, subjects and methodsA FreeStyle Libre Pro® (FSLP) was worn for up to 14 days in blinded mode in 42 patie…

Blood GlucoseAgingPediatricsmedicine.medical_specialtyendocrine system diseasesPopulation030209 endocrinology & metabolismHypoglycemia03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsIn patient030212 general & internal medicineProspective StudiesCognitive impairmenteducationAgededucation.field_of_studyHigh prevalenceContinuous glucose monitoringbusiness.industryBlood Glucose Self-Monitoringnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemiaIncreased riskDiabetes Mellitus Type 2Geriatrics and GerontologybusinessAge and ageing
researchProduct

Are older patients with diabetes still being overtreated in French long-term care homes?

2020

Abstract Background Diabetes management has not been evaluated in French nursing homes (NHs) for 10 years. Objectives The present study aimed to compare the management of diabetes with guidelines in older patients living in NHs. Design Observational, retrospective and multicentre study carried out in 13 NH in the Cote d’Or region of France. Settings and subjects Between January and June 2018, all NH residents older than 65 years and known to have diabetes (n = 148) were included. Methods Epidemiological, clinical and biological data and diabetes characteristics were collected from the medical records. Results The average glycated haemoglobin (HbA1C) was 7.2 ± 1.2%. In total, 51% of patients…

Blood GlucoseAgingmedicine.medical_specialty030209 endocrinology & metabolismHypoglycemia03 medical and health sciences0302 clinical medicineDiabetes managementInternal medicineDiabetes mellitusEpidemiologymedicineHumansHypoglycemic Agents030212 general & internal medicineAgedRetrospective StudiesBlood glucose monitoringmedicine.diagnostic_testbusiness.industryBlood Glucose Self-MonitoringMedical recordGeneral Medicinemedicine.diseaseLong-Term CareLong-term careDiabetes Mellitus Type 2Observational studyFranceGeriatrics and GerontologybusinessAge and Ageing
researchProduct